Cancer Institute A national cancer institute
designated cancer center
Profile http://med.stanford.edu/profiles/cancer/researcher/Calvin_Kuo/
Email this profile
Portrait View Larger

Calvin Kuo

Academic Appointments

  • Professor of Medicine (Hematology) and, by courtesy, of Chemical and Systems Biology

Key Documents

Contact Information

  • Clinical Offices
    Hematology Clinic 300 Pasteur Dr A175 MC 5312 Stanford, CA 94305
    Tel Work (650) 498-6000 Fax (650) 725-8950
    Hematology Clinic 875 Blake Wilbur Dr Clinic C MC 5820 Stanford, CA 94305
    Tel Work (650) 498-6000 Fax (650) 498-5030
  • Academic Offices
    Personal Information
    Email Tel (650) 736-2399
    Not for medical emergencies or patient use

Bio

Clinical Focus

  • Cancer> Hematology
  • Medical Oncology

Academic Appointments

Administrative Appointments

  • Co-lead, Cancer Biology Program, Stanford Cancer Center (2012 - present)

Honors and Awards

  • Consulting Editor, JCI (2012)
  • American Heart Association Innovative Science Award, AHA (2012)
  • Research Chair, NIH Intestinal Stem Cell Consortium, NIH (2009)
  • Transformative R01 Award, NIH (2009)
  • Member, American Society for Clinical Investigation, American Society for Clinical Investigation (2007)
  • Samantha Janower Research Chair, Brain Tumor Society (2005)
View All 11honors and awards of Calvin Kuo

Professional Education

Fellowship: Brigham and Women's Hospital Harvard Medical School MA (2000)
Residency: Brigham and Women's Hospital Harvard Medical School MA (1997)
Medical Education: Stanford University School of Medicine CA (1994)
A.B.: Harvard College, Biochemical Sciences (1987)
M.D./Ph.D.: Stanford University, Cancer Biology (1994)
Internship/ Residency: Brigham and Women's Hospital, Internal Medicine (1997)
View All 7

Research & Scholarship

Current Research and Scholarly Interests

Oncogene discovery in organoid cultures.
We have successfully established primary 3D organoid cultures of diverse tissues and used them to achieve the first in vitro conversion of primary intestine, stomach and pancreas tissue to adenocarcinoma (Ootani et al, Nat Med 2009; Li et al, Nat Med 2014). These organoid systems comprise an robust in vitro system for the functional validation of putative oncogenic loci which are identified in whole-genome cancer surveys such as TCGA. We collaborate extensively with systems biologists to interrogate large-scale cancer genomics datasets.

Intestinal stem/progenitor biology.
The complete regeneration of the epithelial lining of the intestine every 5-7 days renders the intestine a model system for studying stem cell behaviors. We are investigating the regulation of the intestinal stem cell (ISC) compartment by extracellular signals such as Wnts, using adenoviral and conditional knockout approaches, and have found that Bmi1+ ISC are strongly injury-inducible versus the homeostatic function of Lgr5+ ISC (c.f. Yan et al, PNAS 2012, Barry et al, Nature 2013). Further, we have derived robust organoid methods for prolonged culture of and ex vivo expansion of primary intestinal tissue, with preservation of ISCs and recapitulation of the Wnt- and Notch-dependent ISC niche, even allowing peristalsis (Ootani et al, Nat Med 2009).

Endothelial cell regulation of physiology,
How do endothelial cells regulate physiology of their host organs? The liver hepatocyte appears particularly responsive to its host endothelial cells. We are investigating effects of VEGF inhibition on hepatocyte functions in terms of Epo synthesis, erythropoiesis (Tam et al, Nat Med 2006) and metabolic pathways. We have found that FDA-approved VEGF inhibitors such as aflibercept improve glucose tolerance and can treat animal models of diabetes, by stimulating cross-talk between the hypoxia and insulin signaling pathways, with sensitization of hepatic insulin signaling (Wei et al., Nature Med 2013a; Taniguchi et al., Nat. Med., 2013b). We are also correlating these changes with anti-tumor response and survival in cancer patients receiving VEGF inhibitors, as potential surrogate biomarkers of efficacy.

Angiogenesis.
We are interested in determining functions of novel molecules regulating angiogenesis including receptors such as GPCRs, microRNAs and secreted molecules. We found that GPR124 is essential for developmental brain angiogenesis (Kuhnert et al, Science 2010) and are exploring this receptor's function in adult pathophysiology. We have several active projects in stroke and blood-brain barrier (BBB) biology. We are also exploring the functions of the endothelial miRNA miR-126 in adults using conditional ko mice (Kuhnert et al, Development 2008). We have extensive experience using adenoviral expression of soluble receptor ectodomains to inhibit diverse angiogenic pathways including VEGF and PDGFRb. Loss-of-function phenotypes would simulate the effects of pharmacologic inhibition of novel targets for anti-angiogenic therapy of cancer and ocular disorders.

Teaching

Courses

2013-14

Publications

Publications

Publication tag cloud

Publication Topics

View All 28

Stanford Medicine Resources:

Footer Links: